Literature DB >> 31937078

Dexmedetomidine reduces myocardial ischemia-reperfusion injury in rats through PI3K/AKT/GSK-3β signaling pathway.

Xiushuang Zhang1, Mingjun Xu1, Xiangming Che1, Xiuling Cao1, Xiaoguang Li2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31937078     DOI： 10.23736/S0026-4725.19.05102-8

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN： 0026-4725            Impact factor:   1.347


× No keyword cloud information.
  2 in total

1.  Dexmedetomidine promotes cell proliferation and inhibits cell apoptosis by regulating LINC00982 and activating the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) signaling in hypoxia/reoxygenation-induced H9c2 cells.

Authors:  Tao Wang; Zhen Li; Shuyun Xia; Zhixin Xu; Xiaofang Chen; Hu Sun
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 2.  Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine.

Authors:  Meng Sun; Rong Wang; Rui Xia; Zhengyuan Xia; Zhilin Wu; Tingting Wang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.